Filing Details

Accession Number:
0001725160-23-000035
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-02-14 19:10:55
Reporting Period:
2023-02-13
Accepted Time:
2023-02-14 19:10:55
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1725160 Zentalis Pharmaceuticals Inc. ZNTL Pharmaceutical Preparations (2834) 823607803
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1807359 Epperly Melissa B, C/O Zentalis Pharmaceuticals, Inc.
1359 Broadway, Suite 1710
New York NY 10018
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-02-13 2,624 $20.42 397,275 No 4 S Direct
Common Stock Disposition 2023-02-14 5,227 $19.98 392,048 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
  2. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $19.79 to $20.64. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires August 15, 2023.
  4. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $19.77 to $20.30. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.